B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume -, Issue -, Pages 1-14
Publisher
Informa UK Limited
Online
2019-07-06
DOI
10.1080/14712598.2019.1641196
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
- (2019) Hareth Nahi et al. PLoS One
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells
- (2019) Haiming Chen et al. LEUKEMIA RESEARCH
- Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
- (2018) Kevin M. Friedman et al. HUMAN GENE THERAPY
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
- (2018) Jooeun Bae et al. LEUKEMIA
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Promise of Immune Therapies in Multiple Myeloma
- (2018) Kenneth C. Anderson Journal of Oncology Practice
- bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.
- (2018) Noopur S. Raje et al. JOURNAL OF CLINICAL ONCOLOGY
- APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
- (2018) Yu-Tzu Tai et al. LEUKEMIA
- Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
- (2018) Shih-Feng Cho et al. Frontiers in Immunology
- Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
- (2018) Yu-Tzu Tai et al. Frontiers in Immunology
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
- (2018) Suzanne Trudel et al. LANCET ONCOLOGY
- Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells
- (2018) Krista Kinneer et al. LEUKEMIA
- Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement
- (2017) Elisabeth Schuh et al. JOURNAL OF IMMUNOLOGY
- Multiple myeloma
- (2017) Shaji K. Kumar et al. Nature Reviews Disease Primers
- Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication
- (2016) G. An et al. BLOOD
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
- (2016) Y.-T. Tai et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
- (2016) Lydia Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma
- (2016) E. Sanchez et al. CLINICAL CANCER RESEARCH
- Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
- (2016) M. V. Maus et al. CLINICAL CANCER RESEARCH
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- (2016) Michael Ghermezi et al. HAEMATOLOGICA
- A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
- (2016) S Hipp et al. LEUKEMIA
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- (2016) Michael Ghermezi et al. HAEMATOLOGICA
- Targeting B-cell maturation antigen in multiple myeloma
- (2015) Yu-Tzu Tai et al. Immunotherapy
- CAR therapy: the CD19 paradigm
- (2015) Michel Sadelain JOURNAL OF CLINICAL INVESTIGATION
- Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
- (2015) Joshua Seth Eaton et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow
- (2015) T Matthes et al. LEUKEMIA
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
- (2015) I. Gravanis et al. ONCOLOGIST
- γ-secretase directly sheds the survival receptor BCMA from plasma cells
- (2015) Sarah A. Laurent et al. Nature Communications
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL
- (2014) M. J. Benson et al. JOURNAL OF IMMUNOLOGY
- A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs
- (2014) A. E. Prota et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma
- (2013) L. Bolkun et al. ANNALS OF HEMATOLOGY
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- B-cell maturation antigen is modified by a single N-glycan chain that modulates ligand binding and surface retention
- (2013) H.-W. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
- (2012) Y.-T. Tai et al. BLOOD
- Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
- (2012) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas
- (2011) M. Guadagnoli et al. BLOOD
- Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow
- (2011) T. Matthes et al. BLOOD
- Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders
- (2011) Jooeun Bae et al. BRITISH JOURNAL OF HAEMATOLOGY
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis
- (2009) Y. Zheng et al. BLOOD
- APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop
- (2009) Jérôme Moreaux et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells
- (2008) E. Belnoue et al. BLOOD
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started